Transarterial chemotherapy with zinostatin stimalamer for hepatocellular carcinoma

Takuji Okusaka, Shuichi Okada, Hiroshi Ishii, Masafumi Ikeda, Hidekazu Nakasuka, Hiroyasu Nagahama, Ryoko Iwata, Hiroyoshi Furukawa, Kenichi Takayasu, Yukihiro Nakanishi, Michiie Sakamoto, Setsuo Hirohashi, Masayoshi Yoshimori

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Zinostatin stimalamer (SMANCS) is a lipophilic intra-arterial chemotherapeutic agent for hepatocellular carcinoma (HCC). Thirty HCC patients underwent transcatheter arterial injection of 4 mg SMANCS-lipiodol emulsion. Their responses were evaluated by computed tomography 1 month after treatment. Complete response (CR) was defined as disappearance or 100% necrosis of all tumors. Partial response (PR) was defined as @? 50% reduction and/or @? 50% necrosis. We regarded the lipiodol accumulation in tumors as being necrotic. CR and PR were observed in 8 patients (27%) and 4 patients (13%), respectively, and the overall response rate (CR + PR/all patients) was 40% (12/30). Of 12 patients whose serum α-fetoprotein levels had been more than 200 ng/ml before treatment, 5 patients (42%) showed more than 50% reduction in this level within 1 month after treatment. Toxicity was quite acceptable, although grade 4 toxicity (WHO) was observed as liver dysfunction in 1 patient. Transarterial chemotherapy with SMANCS, which is well tolerated, appears to have moderate antitumor effect in patients with HCC.

Original languageEnglish
Pages (from-to)276-283
Number of pages8
JournalOncology
Volume55
Issue number4
DOIs
Publication statusPublished - 1998 Jul
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Drug Therapy
Ethiodized Oil
Necrosis
Fetal Proteins
poly(maleic acid-styrene)neocarzinostatin
Emulsions
Liver Diseases
Neoplasms
Therapeutics
Tomography
Injections
Serum

Keywords

  • Hepatocellular carcinoma
  • Transarterial chemotherapy
  • Zinostatin stimalamer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Okusaka, T., Okada, S., Ishii, H., Ikeda, M., Nakasuka, H., Nagahama, H., ... Yoshimori, M. (1998). Transarterial chemotherapy with zinostatin stimalamer for hepatocellular carcinoma. Oncology, 55(4), 276-283. https://doi.org/10.1159/000011863

Transarterial chemotherapy with zinostatin stimalamer for hepatocellular carcinoma. / Okusaka, Takuji; Okada, Shuichi; Ishii, Hiroshi; Ikeda, Masafumi; Nakasuka, Hidekazu; Nagahama, Hiroyasu; Iwata, Ryoko; Furukawa, Hiroyoshi; Takayasu, Kenichi; Nakanishi, Yukihiro; Sakamoto, Michiie; Hirohashi, Setsuo; Yoshimori, Masayoshi.

In: Oncology, Vol. 55, No. 4, 07.1998, p. 276-283.

Research output: Contribution to journalArticle

Okusaka, T, Okada, S, Ishii, H, Ikeda, M, Nakasuka, H, Nagahama, H, Iwata, R, Furukawa, H, Takayasu, K, Nakanishi, Y, Sakamoto, M, Hirohashi, S & Yoshimori, M 1998, 'Transarterial chemotherapy with zinostatin stimalamer for hepatocellular carcinoma', Oncology, vol. 55, no. 4, pp. 276-283. https://doi.org/10.1159/000011863
Okusaka T, Okada S, Ishii H, Ikeda M, Nakasuka H, Nagahama H et al. Transarterial chemotherapy with zinostatin stimalamer for hepatocellular carcinoma. Oncology. 1998 Jul;55(4):276-283. https://doi.org/10.1159/000011863
Okusaka, Takuji ; Okada, Shuichi ; Ishii, Hiroshi ; Ikeda, Masafumi ; Nakasuka, Hidekazu ; Nagahama, Hiroyasu ; Iwata, Ryoko ; Furukawa, Hiroyoshi ; Takayasu, Kenichi ; Nakanishi, Yukihiro ; Sakamoto, Michiie ; Hirohashi, Setsuo ; Yoshimori, Masayoshi. / Transarterial chemotherapy with zinostatin stimalamer for hepatocellular carcinoma. In: Oncology. 1998 ; Vol. 55, No. 4. pp. 276-283.
@article{00fa9dd7e0534129aafeb67bbbcd6f77,
title = "Transarterial chemotherapy with zinostatin stimalamer for hepatocellular carcinoma",
abstract = "Zinostatin stimalamer (SMANCS) is a lipophilic intra-arterial chemotherapeutic agent for hepatocellular carcinoma (HCC). Thirty HCC patients underwent transcatheter arterial injection of 4 mg SMANCS-lipiodol emulsion. Their responses were evaluated by computed tomography 1 month after treatment. Complete response (CR) was defined as disappearance or 100{\%} necrosis of all tumors. Partial response (PR) was defined as @? 50{\%} reduction and/or @? 50{\%} necrosis. We regarded the lipiodol accumulation in tumors as being necrotic. CR and PR were observed in 8 patients (27{\%}) and 4 patients (13{\%}), respectively, and the overall response rate (CR + PR/all patients) was 40{\%} (12/30). Of 12 patients whose serum α-fetoprotein levels had been more than 200 ng/ml before treatment, 5 patients (42{\%}) showed more than 50{\%} reduction in this level within 1 month after treatment. Toxicity was quite acceptable, although grade 4 toxicity (WHO) was observed as liver dysfunction in 1 patient. Transarterial chemotherapy with SMANCS, which is well tolerated, appears to have moderate antitumor effect in patients with HCC.",
keywords = "Hepatocellular carcinoma, Transarterial chemotherapy, Zinostatin stimalamer",
author = "Takuji Okusaka and Shuichi Okada and Hiroshi Ishii and Masafumi Ikeda and Hidekazu Nakasuka and Hiroyasu Nagahama and Ryoko Iwata and Hiroyoshi Furukawa and Kenichi Takayasu and Yukihiro Nakanishi and Michiie Sakamoto and Setsuo Hirohashi and Masayoshi Yoshimori",
year = "1998",
month = "7",
doi = "10.1159/000011863",
language = "English",
volume = "55",
pages = "276--283",
journal = "Oncology (Switzerland)",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Transarterial chemotherapy with zinostatin stimalamer for hepatocellular carcinoma

AU - Okusaka, Takuji

AU - Okada, Shuichi

AU - Ishii, Hiroshi

AU - Ikeda, Masafumi

AU - Nakasuka, Hidekazu

AU - Nagahama, Hiroyasu

AU - Iwata, Ryoko

AU - Furukawa, Hiroyoshi

AU - Takayasu, Kenichi

AU - Nakanishi, Yukihiro

AU - Sakamoto, Michiie

AU - Hirohashi, Setsuo

AU - Yoshimori, Masayoshi

PY - 1998/7

Y1 - 1998/7

N2 - Zinostatin stimalamer (SMANCS) is a lipophilic intra-arterial chemotherapeutic agent for hepatocellular carcinoma (HCC). Thirty HCC patients underwent transcatheter arterial injection of 4 mg SMANCS-lipiodol emulsion. Their responses were evaluated by computed tomography 1 month after treatment. Complete response (CR) was defined as disappearance or 100% necrosis of all tumors. Partial response (PR) was defined as @? 50% reduction and/or @? 50% necrosis. We regarded the lipiodol accumulation in tumors as being necrotic. CR and PR were observed in 8 patients (27%) and 4 patients (13%), respectively, and the overall response rate (CR + PR/all patients) was 40% (12/30). Of 12 patients whose serum α-fetoprotein levels had been more than 200 ng/ml before treatment, 5 patients (42%) showed more than 50% reduction in this level within 1 month after treatment. Toxicity was quite acceptable, although grade 4 toxicity (WHO) was observed as liver dysfunction in 1 patient. Transarterial chemotherapy with SMANCS, which is well tolerated, appears to have moderate antitumor effect in patients with HCC.

AB - Zinostatin stimalamer (SMANCS) is a lipophilic intra-arterial chemotherapeutic agent for hepatocellular carcinoma (HCC). Thirty HCC patients underwent transcatheter arterial injection of 4 mg SMANCS-lipiodol emulsion. Their responses were evaluated by computed tomography 1 month after treatment. Complete response (CR) was defined as disappearance or 100% necrosis of all tumors. Partial response (PR) was defined as @? 50% reduction and/or @? 50% necrosis. We regarded the lipiodol accumulation in tumors as being necrotic. CR and PR were observed in 8 patients (27%) and 4 patients (13%), respectively, and the overall response rate (CR + PR/all patients) was 40% (12/30). Of 12 patients whose serum α-fetoprotein levels had been more than 200 ng/ml before treatment, 5 patients (42%) showed more than 50% reduction in this level within 1 month after treatment. Toxicity was quite acceptable, although grade 4 toxicity (WHO) was observed as liver dysfunction in 1 patient. Transarterial chemotherapy with SMANCS, which is well tolerated, appears to have moderate antitumor effect in patients with HCC.

KW - Hepatocellular carcinoma

KW - Transarterial chemotherapy

KW - Zinostatin stimalamer

UR - http://www.scopus.com/inward/record.url?scp=0031840933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031840933&partnerID=8YFLogxK

U2 - 10.1159/000011863

DO - 10.1159/000011863

M3 - Article

VL - 55

SP - 276

EP - 283

JO - Oncology (Switzerland)

JF - Oncology (Switzerland)

SN - 0030-2414

IS - 4

ER -